The Centre for Clinical Translation applies insights gained through fundamental research to develop novel pharmacological and behavioural therapies of neurological diseases. Effective translational neuroscience requires continuous interactions of fundamental and clinical neuroscientists, which are fostered by the Centre.
The research groups in the Centre use molecular, optogenetic, physiological and network system techniques to advance the understanding and treatment of a range of important neurological conditions, including movement and balance, chronic pain, stroke, epilepsy and epigenetic disorders. This has led, specifically, to successful novel clinical trials and applications in vestibular dysfunction, painful neuropathy, acute stroke, Friedreich's ataxia, and drug re-profiling for epilepsy.
The Centre facilities include laboratories with equipment for cutting-edge techniques to study light and genetics-based functional imaging approaches to behaviour, as well as Clinical Units which enable innovative diagnosis and treatment of patients with sensorimotor disorders. The Centre research groups also utilise the Clinical Research and Imaging Facilities.
The principal investigators at the Centre participate in UK and international academic and industry research consortia. Collaborations with pharmaceutical companies are directed to bridge the gap between pre-clinical developments and their successful clinical applications.
Research groups and key individuals
Head of Clinical Translation
Professor Praveen Anand is Professor of Clinical Neurology and the Head of Centre for Clinical Translation, and is based at Hammersmith Hospital campus. His research focuses on pathophysiological and molecular mechanisms in human sensory neuropathies and chronic pain syndromes.
Deputy Head of Clinical Translation
Dr Michael R Johnson's research involves the application of network approaches integrated with large-scale genetic data to connect transcriptional programmes to hippocampus function in health and disease.